Festival of Biologics’ Post

Santa Ana Bio, Inc. launches with $168M in Series A and B funding to develop precision therapies for autoimmune and inflammatory diseases, leveraging advanced proteomic, transcriptomic, and genomic techniques for targeted treatments. Their lead programs include SAB01, a bi-specific antibody targeting mast cells in allergic diseases; SAB03, a PD-1 agonist for rheumatoid arthritis; and SAB05, an antibody-glucocorticoid conjugate for severe inflammatory conditions, all set to enter clinical trials next year. More on this pipeline in our full coverage, link in the comments. #BiotechNews #PrecisionMedicine #AutoimmuneDisease #InflammatoryDiseases #RheumatoidArthritis #BiotechFunding

🌟 New Article Alert: Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors🌟 Fab Biopharma is pioneering bispecific soluble receptor therapies to address complex autoimmune diseases like Sjögren’s and lupus. These innovative molecules engage both T and B cells while avoiding the cross-linking risks of traditional bispecific antibodies, offering a more precise, targeted approach. In our newest article authored by Fab Biopharma Co-Founders Reiner Gentz, Ph.D and Gardiner Smith, J.D, discover how our receptors are designed to modulate, not suppress, immune responses — a critical advancement for diseases where immune function must be carefully balanced. Read the full article here: https://lnkd.in/eG8BgmbN #DrugDevelopment #WomensHealth #BiopharmaInnovation #LifeSciences

Cutting-edge insights for Psoriatic Arthritis specialists! Siebert, et al.'s study delves into #guselkumab's impact on different immunologic partameters and clinical responses in biologic-naïve or TNFi-IR patients. Results of the latest analyses from #DISCOVER-1, #DISCOVER-2, #COSMOS trials now available on the #IMIDforum. Explore the nuanced connections between elevated IL-22, IL-17A, BD-2 levels, and robust skin responses following #guselkumab therapy. Siebert, et al.'s findings support #guselkumab as a modulator of IL-23/Th17 cell signaling in challenging PsA cases. Delve into the specifics with our exclusive slide deck, only at #IMIDforum: https://lnkd.in/eSq377cC

Discovery Life Sciences has a robust #biorepository of #biospecimens available from #autoimmunedisease patients available for immediate shipment to your facility. PBMCs, plasma, serum and FFPE are all available. Send me a DM if you need an inventory report! #PBMCs #FFPE #tissues #rheumatoidarthritis #SLE #lupus #psoriasis #autoimmune #researchanddevelopment #clinicalsamples

So lucky to be able to work so closely with Cheerag and learn from his experience and expertise, I want to congratulate Cheerag Shirodaria on his latest publication in Cardiovascular Research. Identification and targeting coronary inflammation is an emerging strategy for reducing cardiovascular risk. This important trial, utilising Caristo’s CaRi-Heart technology, showed that Orticumab, a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease, significantly reduced coronary inflammation. Read the new peer-reviewed publication by Cheerag Shirodaria, M.D., VP and TA Head, Cardiovascular/Metabolism at Fortrea, and additional authors. #coronaryinflammation #cardiovasculardisease

348 >>> 6 , yowza!!! (now, that's actionable!) ⭐ Please consider checking out the latest study from Van Eijck et al. on biomarkers for drug response and disease progression in patients with pancreatic ductal adenocarcinoma (PDAC). In this study, they used an Explore 384 panel to derive a 6-protein model that predicts PDAC progression during FOLFIRINOX therapy with high accuracy. The study found that "proteins had superior predictive accuracy to genes" when compared to transcriptomics. This study sheds light on the importance of protein markers in predicting disease progression during FOLFIRINOX therapy. [[ Great stuff Casper van Eijck . Thanks from the species for this! ]] Conclusions In summary, our six-protein FFX-IPEP signature is a liquid biomarker with a solid potential to predict PDAC progression early during FOLFIRINOX treatment. In our cohort, the FFX-IPEP signature predicted PDAC progression during FOLFIRINOX more accurately than changes in CA19-9. Future studies should expand to predict progression under different chemotherapies. This expansion could guide more effective personalized treatment selection while at the same time avoiding ineffective but toxic treatment. #protein #biomarkers #cancerresearch #PDAC #FOLFIRINOXtherapy

This study by FitzGerald, et al. evaluates the association of serum biomarkers with baseline PsA disease activity, the pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib. The authors found that deucravacitinib impacted the levels of biomarkers in the TYK2 signalling pathway, including IL-23 and Type I IFN, and those related to collagen matrix turnover. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #PsoriaticArthritis https://ow.ly/cfIg50Sn6kT

Exazym® is a new method for ultra-sensitive detection of low-abundance biomarkers. See the chart showing the results of applying BOLD to a standard interleukin 4 ELISA vs. a standard ELISA. IL-4 plays an important role in, e.g., regulating antibody production, hematopoiesis, and inflammation, and is a biomarker for several diseases. Visit www.Cavidi.se to learn more. #Immunoassay #SignalAmplification #ELISA #Cavidi #Exazym

🔬 Enhanced Enzyme Delivery for Pompe Disease Pompe disease is a severe genetic disorder caused by the buildup of glycogen in the body's cells, leading to progressive muscle weakness and respiratory problems. Even if treated with the current standard treatment, enzyme replacement therapy (ERT), those with infant-onset Pompe rarely survive beyond adolescence.   At Sutura Therapeutics, we're pioneering improved treatments for Pompe disease using our innovative stapled peptides. By conjugating the therapeutic enzyme to these peptides we have been able to significantly enhance its effectiveness and delivery to the muscle cells.   A fluorescent reporter protein vividly demonstrates this advancement, showcasing how our peptides can achieve greater cellular uptake.   Stay connected with us to learn more about how our solutions are transforming the landscape of Pompe disease treatment.   #PompeDisease #RareDiseases #HealthcareInnovation

We are continuously working on exciting new research in the pulmonary fibrosis team! Our recent focus on the FIB-NIT™ panel has yielded promising results. NordicPRO-C3™ and NordicPRO-C6™ have demonstrated strong prognostic and pharmacodynamic value; their efficacy has been validated in multiple studies, underscoring their reliability and robustness as biomarkers. The inclusion of CTX-III as a new biomarker adds significant insight into mode-of-action. Thus, the FIB-NIT™ panel enhances the ability to predict disease progression and treatment response, paving the way for more personalized and effective therapeutic strategies. If you want to learn more, contact Jannie M. B. Sand or Sarah Rønnow. FIB -NIT™ is an innovative biomarker panel that utilizes fibrotic processes with superior pharmacodynamic and prognostic performance to investigate dynamics within fibrotic diseases, including understanding drug efficacy in such indications. This has been demonstrated in over 100 publications in relevant peer-reviewed scientific journals. #PulmonaryFibrosis #FIBNIT #Biomarkers #DiseaseProgression #PersonalizedMedicine